Experts say that improving heart and metabolic health may be key to helping people with severe mental illness live longer, ...

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, ...

A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without reaching a ...

The GLP-1 moment signals how quickly a high-demand therapy can upend established care patterns—and how similar innovations may emerge in the years ahead.

Add Yahoo as a preferred source to see more of our stories on Google. GLP-1 agonists like Ozempic are primarily used to treat type 2 diabetes. Its popularity has even influenced wholesale retailer ...

As the GLP-1 trend expands, a 'halo effect' is developing. Consumers in families of GLP-1 users are increasingly eating GLP-1 ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

Young, affluent and health‑driven, GLP‑1 users are reshaping food retail with demand for protein‑rich, nutrient‑dense and convenient meals.

Glucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have gained popularity globally, not just for managing type 2 diabetes but also due to ...